Fidelis Capital Partners’s Idexx Laboratories IDXX Stock Holding History

Fidelis Capital Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$469K	Buy	834 +78	+10%	+$50K	0.03%	330
2025 Q4	$511K	Sell	756 -41	-5%	-$27.9K	0.04%	304
2025 Q3	$509K	Buy	797 +20	+3%	+$12.1K	0.04%	301
2025 Q2	$485K	Buy	777 +27	+4%	+$12.9K	0.04%	268
2025 Q1	$328K	Buy	750 +18	+2%	+$7.82K	0.03%	301
2024 Q4	$343K	Sell	732 -134	-15%	-$58.8K	0.03%	318
2024 Q3	$397K	Sell	866 -22	-2%	-$10.7K	0.05%	270
2024 Q2	$415K	Sell	888 -89	-9%	-$44.7K	0.06%	236
2024 Q1	$528K	Buy	977 +59	+6%	+$32.2K	0.08%	204
2023 Q4	$510K	Buy	918 +347	+61%	+$163K	0.11%	167
2023 Q3	$250K	Sell	571 -9	-2%	-$4.49K	0.09%	224
2023 Q2	$291K	Buy	580 +44	+8%	+$21.1K	0.11%	204
2023 Q1	$262K	Buy	+536	New	+$257K	0.11%	201

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelis Capital Partners's IDXX Position: Q1 2026 in Review

Fidelis Capital Partners increased its Idexx Laboratories (IDXX) stake by 10% in Q1 2026, buying an estimated $50K and bringing the position to 834 shares worth $469K. The position accounts for 0.03% of the portfolio, ranked #330.

Fidelis Capital Partners first reported a position in IDXX in Q1 2023 and has held it in 13 quarters since. The position peaked at $528K in Q1 2024. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Fidelis Capital Partners held 834 shares of Idexx Laboratories worth $469K as of Q1 2026.
Fidelis Capital Partners bought 78 Idexx Laboratories shares in Q1 2026, an estimated $50K.
Idexx Laboratories made up 0.03% of Fidelis Capital Partners's portfolio in Q1 2026, its #330 holding.
Fidelis Capital Partners first reported a position in Idexx Laboratories in Q1 2023 and has held it in 13 quarters since.
Fidelis Capital Partners's Idexx Laboratories position peaked at $528K in Q1 2024.
1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.